Assessment of therapeutic potential of and commercial supplements in experimental giardiasis models.

is one of the most common protozoal parasites in humans, and a major cause of diarrheal illness. Treatment of giardiasis relies on metronidazole (MTZ) and other nitroimidazoles which exhibit some limitations, including variable treatment efficacy and parasite-drug resistance. In this work, we investigated the therapeutic effects of the commercial products of and , alone and in combination with MTZ, on giardiasis in experimentally infected hamsters. Parasitological assessments: cysts count, cysts viability and trophozoites count, and histopathological assessment were performed. Results revealed that the percentage of reduction in cysts number in the MTZ, and /MTZ treated groups were of 84.5, 88.9, 82, and 86.1%, respectively, compared to infected non-treated group. While MTZ treated group showed percentage of reduction 79.7%. Regarding the cyst viability, it was reduced by 73.4, 76.9, 64.9, and 70.7%, in the MTZ, and /MTZ treated groups respectively, compared to 61.9% in the MTZ treated group. For the trophozoites, the percentage of reduction was 64.1, 60.2, 59.4, and 47.3%, respectively, compared to 38.6% in MTZ treated group. The examination of duodenal sections revealed remarkable improvement in the histopathological changes in the and the MTZ combination groups. In conclusion, and preparations showed higher anti-giardial activity compared to MTZ, with higher reduction in cyst numbers, viability and trophozoite numbers in the experimentally infected hamsters. Further in vivo trials are recommended using and preparations in increasing doses to reach a higher cure rate.